Creative Touch Permanent Makeup and Aesthetics

Biotin is one of the most commercially promoted supplements for hair, skin, and nail health, and one of the most misleadingly marketed. The distinction the evidence establishes is precise: biotin deficiency produces a well-characterised pattern of seborrheic dermatitis, alopecia, and nail fragility that resolves completely with repletion. In biotin-replete individuals – the overwhelming majority of supplement purchasers – there is no evidence that additional biotin improves hair growth, skin quality, or nail strength. A 2017 systematic review found all 18 published positive cases of biotin supplementation for hair and nail changes involved patients with an underlying deficiency or pathology; in vitro studies confirm that proliferation of non-pathological follicular keratinocytes is not influenced by biotin above deficiency threshold. The clinical value of this entity is in being precise about what biotin does, where it does it, and for whom supplementation is genuinely warranted.

Biotin (vitamin B7, vitamin H) is a water-soluble B vitamin that functions as an obligate covalent cofactor – it is not a simple enzyme activator but is chemically bonded to its target enzymes through an amide linkage with a lysine residue. The enzyme biotinyl protein ligase (BPL) catalyses this covalent attachment, and the enzyme biotinidase performs the reverse, releasing biotin from degraded carboxylase enzymes for recycling. ^[3] This recycling pathway is clinically important: biotinidase deficiency is one of the two primary causes of biotin deficiency syndrome, the other being inadequate dietary intake.

Biotin is required as a cofactor for five carboxylase enzymes in human tissue:

• Acetyl-CoA carboxylase 1 (ACC1): cytoplasmic; rate-limiting step in de novo fatty acid synthesis
• Acetyl-CoA carboxylase 2 (ACC2): mitochondrial; regulates fatty acid oxidation
• Pyruvate carboxylase (PC): gluconeogenesis and anaplerosis
• Propionyl- CoA carboxylase (PCC): odd-chain fatty acid and branched-chain amino acid catabolism
• β-Methylcrotonyl-CoA carboxylase (MCC): leucine catabolism ^[4]

Of these, ACC1 is the most directly skin-relevant – it catalyses the conversion of acetyl-CoA to malonyl-CoA, the committed step in fatty acid synthesis. Without biotin-functional ACC1, cells cannot synthesise long-chain fatty acids endogenously, affecting membrane phospholipid composition, ceramide precursor availability, and the free fatty acid content of the stratum corneum lipid matrix.

Why Keratinocytes Are Particularly Biotin-Sensitive

Not all cell types respond equally to biotin depletion. A comparative study of carboxylase activities across multiple cell types found that keratinocytes and neuronal cells were among the most sensitive to biotin depletion – carboxylase activities in keratinocyte cultures fell to 2–11% of maximal activity in low-biotin conditions, compared to 32–85% in skin fibroblasts under the same conditions. imrpress.com This differential sensitivity is likely the mechanistic basis for the characteristic cutaneous presentation of biotin deficiency – the rapidly proliferating keratinocyte population has a disproportionately high demand for biotin-dependent fatty acid synthesis relative to the slower-cycling fibroblast population beneath it.

The specific vulnerability of keratinocytes to biotin depletion explains why the skin manifestations of deficiency appear at lower levels of insufficiency than systemic metabolic effects. The stratum corneum’s structural lipids – ceramides, free fatty acids, cholesterol – require fatty acid synthesis for their production, and ACC1 is the rate-limiting step in that pathway. A keratinocyte population with compromised ACC1 activity produces a stratum corneum with a qualitatively altered lipid profile, which manifests clinically as the characteristic perioral and periorificial seborrheic rash of biotin deficiency.

The Deficiency Presentation

Biotin deficiency produces a clinically recognisable pattern that is reversible with repletion:

Cutaneous manifestations include seborrheic dermatitis-like rash – characteristically distributed around the eyes, nose, mouth, ears, and groin – alongside generalised dry, scaly skin. The distribution reflects the higher keratinocyte turnover rate at perioral and periorificial sites. Atopic dermatitis-like presentations, skin fragility, and impaired wound healing have also been reported. ^[2]

Hair changes include diffuse alopecia – thinning distributed across the scalp rather than patterned loss – and altered hair texture. The hair follicle is a site of rapid cell division and high keratinocyte turnover; the same ACC1-dependent fatty acid synthesis demand that makes epidermal keratinocytes sensitive to biotin depletion applies to follicular keratinocytes. Hair follicle cycling requires sustained fatty acid synthesis for both the structural keratin production of the hair shaft and the sebaceous lipid environment supporting the follicular unit. dermnetnz.org

Nail changes include brittleness, longitudinal ridging, and splitting – reflecting compromised keratinocyte fatty acid synthesis in the nail matrix. Brittle nail syndrome, a distinct clinical entity characterised by onychoschizia and onychorrhexis, has been reported to respond to biotin supplementation, though the evidence is primarily case series rather than controlled trials, and response is most consistent in patients with demonstrable deficiency or malabsorption. ^[1]

Neurological manifestations – lethargy, depression, paraesthesia, and in severe cases seizures – reflect the high carboxylase sensitivity of neuronal tissue, which parallels keratinocyte sensitivity in the comparative carboxylase study. Cutaneous and neurological manifestations often co-present, and unexplained neurological symptoms alongside the characteristic perioral rash should prompt biotin assessment.

Complete resolution of all cutaneous, hair, and nail manifestations follows biotin repletion – typically within weeks for skin and months for hair regrowth – confirming the direct mechanistic relationship. dermnetnz.org

The Supplementation Myth: Where the Evidence Actually Sits

The commercial biotin supplement market operates on a proposition that the peer-reviewed evidence does not support: that supplementation in healthy, biotin-replete individuals improves hair growth, skin quality, or nail strength. The evidence base, examined honestly, does not sustain this claim.

The most comprehensive review of biotin for hair loss (Patel et al. 2017, Skin Appendage Disorders) identified 18 published cases of biotin supplementation producing clinical improvement in hair or nail changes. In every single case, the patient had an underlying pathology causing or contributing to biotin deficiency – biotinidase deficiency, inflammatory bowel disease, antibiotic-associated gut flora disruption, eating disorders, antiepileptic drug use, or isotretinoin use. Of the women in the hair loss studies who reported improvement, 11% had a pharmacological or gastrointestinal reason for the underlying deficiency, and 35% had co-existing seborrheic dermatitis suggesting multifactorial causation. Not one well-designed study demonstrated hair or nail improvement from biotin supplementation in biotin-replete healthy subjects. ^[1]

The in vitro evidence is equally unambiguous on a specific point: proliferation and differentiation of normal, non-pathological follicular keratinocytes are not influenced by biotin concentrations above deficiency threshold. ^[1] Once carboxylase activity is saturated – which occurs at normal physiological biotin levels – additional biotin provides no further enzymatic benefit. ACC1 activity does not increase above its maximum rate simply because more cofactor is available; the enzyme is already fully biotinylated in a replete state.

The commercial supplement claims compound this problem by typically using doses of 5,000–10,000 µg (5–10 mg) daily – doses 166–333 times the UK Reference Nutrient Intake of 30 µg/day. These supraphysiological doses have a documented practical problem beyond their lack of efficacy: high-dose biotin significantly interferes with immunoassay-based laboratory tests, including thyroid function tests, troponin (cardiac), and hormone panels, because biotin competes with the streptavidin-biotin binding used in many assay systems. The FDA issued a safety communication on this interference in 2017. A client taking 10,000 µg biotin daily may produce falsely normal or falsely abnormal results across multiple blood tests – a clinically meaningful safety concern that most supplement marketing does not mention. ^[1]

Causes of Genuine Deficiency

Understanding who actually has biotin deficiency is necessary for the clinical question to be meaningful. Genuine deficiency is less common than supplement marketing implies but more common than might be assumed in specific populations:

• Biotinidase deficiency: inherited enzyme deficiency impairing biotin recycling; screened at birth in the UK but partial deficiency may be underdiagnosed
• Inflammatory bowel disease (Crohn’s, ulcerative colitis) impairs biotin absorption in the small intestine
• Raw egg white consumption: avidin, a protein in raw egg white, binds biotin with extremely high affinity and prevents absorption; cooking denatures avidin and eliminates this effect
• Prolonged antibiotic use: gut microbiome biotin synthesis contributes to total biotin availability; broad-spectrum antibiotics reduce this contribution
• Antiepileptic drugs (valproate, phenytoin, carbamazepine) impair biotin absorption and increase catabolism
• Isotretinoin use: reported association with biotin deficiency, mechanism not fully characterised; clinically relevant given the co-prescription context
• Pregnancy: increased biotin catabolism during pregnancy is well-documented; marginal deficiency is common and has implications for foetal development
• Parenteral nutrition without biotin supplementation: total parenteral nutrition bypasses dietary biotin intake entirely ^[2]